Molecular Therapeutics Theme 2 Accomplishments

Theme 2: Identify cellular/molecular determinants and clinically relevant biomarkers of treatment response on which to base therapy

Scientific Accomplishments 

Drs. Bepler, Gadgeel, A Schwartz, and Cote, working with Dr. Bollig-Fischer, identified “driver” mutations in non-small cell lung cancer (NSCLC) in African American and European American patients using the Sequenom MassArray system and a multiplexed panel for 214 oncogenic mutations in 26 genes previously identified in NSCLC. African Americans with NSCLC exhibited multiple genetic mutations more frequently than European Americans with a different mutation profile. These results provided impetus for CAP/CLIA certification of the Genomics Core in 2013 for use of custom panels for lung cancer oncogenes and amplifications/deletions.

  • Lead researchers - Drs. Bepler, Gadgeel, and Bollig-Fischer
  • Collaborative researchers - Drs. Schwartz and Cote

Dr. Ratnam, working with Drs. Gadgeel, Shields, Matherly, and Bepler, demonstrated the role of glucocorticoid receptor (GR) status as a determinant of the variability in the sensitivity of non-small cell lung cancer (NSCLC) cells to pemetrexed (PEM), a S-phase-targeted drug in front-line or maintenance therapy  of advanced NSCLC, generally administered with dexamethasone (Dex). Their results predict that in non-squamous NSCLC, S-phase suppression by Dex, combined with a reduction in PEM transport, attenuates responsiveness to PEM and that GR status is an important determinant of tumor variability of this response.  Based on these in vitro results, an investigator-initiated clinical trial (Shields, Lead PI; Ratnam, Gadgeel, Heilbrun, collaborators) is enrolling NSCLC patients who will be screened by RT-PCR for high levels of GRα, then imaged with FLT-PET to test the hypothesis that Dex will decrease S-phase progression, as reflected in decreased activity of thymidine kinase-1.

  • Lead researchers - Drs. Ratnam. Gadgeel, Shields, Matherly and Bepler.
  • Collaborative researcher - Dr. Heilbrun

The Latest From Karmanos Cancer Institute

News

Karmanos Cancer Institute presents 2021 Heroes of Cancer Awards

The Barbara Ann Karmanos Cancer Institute is pleased to announce the winners of its 2021 Heroes of Cancer Awards. This year's event celebrates Kar...

Read More

Karmanos Cancer Institute partners with The Toledo Clinic to establish a new cancer center in Northwest Ohio

The Barbara Ann Karmanos Cancer Institute is pleased to announce that it has entered into a partnership with The Toledo Clinic to establish a new ...

Read More

Father with colorectal cancer gives credit to daughter for saving his life

After serving for 20 years in the United States Navy as a submarine sailor, John Lacks retired and transitioned to life with his family, including...

Read More